Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05682144 · ClinicalTrials.gov registry record · Phase 1
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
A Phase 1 study of Mucopolysaccharidosis IH/S and Mucopolysaccharidosis IS, sponsored by Immusoft of CA.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT05682144 is a Phase 1 study of Mucopolysaccharidosis IH/S and Mucopolysaccharidosis IS that is actively recruiting participants, run by Immusoft of CA. The registered enrollment target is 2 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05682144, a Phase 1 study of Mucopolysaccharidosis IH/S and Mucopolysaccharidosis IS, is actively recruiting participants, sponsored by Immusoft of CA.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
Conditions Studied
Interventions
- BIOLOGICAL Autologous Plasmablasts (B cells)
Study Locations (2)
California
- UCSF Benioff Children's Hospital Oakland - Oakland
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2039-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05682144
The ClinicalTrials.gov registry entry for NCT05682144 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immusoft of CA, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mucopolysaccharidosis IH/S appearing as the primary indexed condition, and to 1 intervention - of which Autologous Plasmablasts (B cells) is the first listed.
NCT05682144 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05682144 about?
NCT05682144 is a clinical study titled "ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I". A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
What is the current status of trial NCT05682144?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-04-12. Estimated completion is 2039-06-01.
What conditions does trial NCT05682144 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS.
What interventions are being tested in trial NCT05682144?
The interventions under investigation include: Autologous Plasmablasts (B cells) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05682144?
This trial is sponsored by Immusoft of CA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05682144 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.